Humanwell Healthcare (600079.SS) traded flat 0 % during a 24 hours period ending at 10:07 PM Central Europe on Tuesday 27th. One Humanwell Healthcare stock can currently be bought for about CNY 19.5 on popular exchanges. Current supply of Humanwell Healthcare stocks is 1.6 bn. Humanwell Healthcare has a current market capitalization of CNY 32.3 bn and approximately CNY 228.5 mn worth of Humanwell Healthcare was traded on exchanges in the last 24 hours. Since last month end, Humanwell Healthcare has traded 4.73 % up. Simple moving average of last 200 days is at CNY 18.02. The highest price of past 52 weeks was recorded at CNY 21.68 on 10/30/2025. 52 weeks low was at CNY 16.03 on 06/22/2026.
Here is how related stocks have performed in the past 24 hours:
Shaanxi Energy Investment (001286.SZ) traded flat 0 % and now trades at CNY 9.84. Current market capitalisation for Shaanxi Energy Investment is CNY 37.9 bn.
Loongson L (688047.SS) traded flat 0 % and now trades at CNY 91.6. Current market capitalisation for Loongson L is CNY 38.1 bn. China’s technology sector remains a key driver of market sentiment as the market experiences a broader pullback. The Shanghai Stock Exchange’s “Sci‑Tech 50” index has attracted a record net inflow of around 240 billion yuan in the last week, underscoring investor confidence in AI and semiconductor growth. Eight Sci‑Tech 50 constituents have released their third‑quarter results, showing strong revenue and profit momentum that supports the sector’s valuation profile. Leading firms such as Cambricon, Haiguang Information and other chip makers report robust demand for AI compute and semiconductor products, with continued investment in research and development. The sector’s performance has prompted a wave of share‑buyback and stake‑increase plans, further reinforcing investor trust. Overall, the market consensus indicates that technology will remain a central pillar of China’s capital markets, with solid fundamentals and ongoing innovation sustaining its appeal.
Jiangsu Etern (600105.SS) traded flat 0 % and now trades at CNY 25.3. Jiangsu Etern has a market capitalisation of CNY 38.6 bn. Current price/earnings ratio for Jiangsu Etern is 59.61. On October 26, 2026, the market for Jiangsu Etern Co. Ltd. experienced a modest decline, reflecting broader volatility in the technology sector. Shares fell after a rally that began in mid‑June, as investors adjusted expectations for the company’s earnings growth. The downturn coincided with a broader correction in the semiconductor and optical‑communication segments, where many peers also saw share prices retract. Analysts noted that the company’s recent quarterly reports had not yet been released, limiting fresh information to guide valuation. Market participants, increasingly cautious amid mixed economic signals, appeared to be reassessing the sustainability of past growth rates. As a result, the trading session concluded with a slight downward shift for Jiangsu Etern, consistent with the overall softness observed across the technology and communication industries.
Hunan Yuneng New Energy Ba (301358.SZ) traded flat 0 % and now trades at CNY 44.36. Current market capitalisation for Hunan Yuneng New Energy Ba is CNY 38.5 bn.
Shanghai Fosun Pharmaceuti-h (2196.HK) traded up 1.03 % and now trades at HKD 16.43. Current market capitalisation for Shanghai Fosun Pharmaceuti-h is HKD 44.5 bn. Current price/earnings ratio for Shanghai Fosun Pharmaceuti-h is 11.33. Shanghai Fosun Pharmaceutical (Group) has released its latest quarterly financial figures at an all‑quarter conference. Analysts anticipate a modest rise in earnings per share for the period, with the company’s revenue expected to show a small increase compared to the same quarter last year. Looking ahead, consensus estimates project a further improvement in earnings for the full fiscal year, while the overall revenue outlook remains slightly above the previous year’s level. The data suggest a continued, albeit gradual, strengthening of the company’s financial performance, reflecting stable growth in both profitability and sales volume.
About Humanwell Healthcare
Humanwell Healthcare Group Co Ltd. is a health care company based in Wuhan, China that specializes in the development and sale of pharmaceuticals. The company produces and markets anesthetics, analgesics, central nerve system drugs, and other products worldwide. Their website is www.humanwell.com.cn and they are listed on the Shanghai Stock Exchange. Their IPO date is 1997-05-22.